S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
Dividend King Genuine Parts Company Upgraded On Profit Guidance
Biden To Unleash "Choke Point" Operation On America? (Ad)
11 Best Consumer Discretionary Stocks of 2023
The Bottom Is In For Accenture
Biden To Unleash "Choke Point" Operation On America? (Ad)
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
NYSE:GMED

Globus Medical - GMED Stock Forecast, Price & News

$53.14
+0.84 (+1.61%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$51.92
$53.15
50-Day Range
$51.83
$79.63
52-Week Range
$50.92
$81.78
Volume
1.24 million shs
Average Volume
1.46 million shs
Market Capitalization
$5.33 billion
P/E Ratio
28.57
Dividend Yield
N/A
Price Target
$70.91

Globus Medical MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
33.4% Upside
$70.91 Price Target
Short Interest
Bearish
5.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.75mentions of Globus Medical in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.26 M Sold Last Quarter
Proj. Earnings Growth
10.00%
From $2.30 to $2.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.06 out of 5 stars

Medical Sector

30th out of 989 stocks

Surgical & Medical Instruments Industry

1st out of 99 stocks


GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

Globus Medical (NYSE:GMED) Downgraded by StockNews.com
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Bear of the Day: NuVasive (NUVA)
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Globus Medical (GMED) Tops Q4 Earnings Estimates
Globus Medical Earnings Preview
Globus Medical: Back Pains
GMED Tanks on NuVasive Deal
Globus Medical and NuVasive announce merger agreement
15 Largest Orthopedic Companies in the World
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
2/21/2023
Today
3/24/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.91
High Stock Price Forecast
$78.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+33.4%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$190.17 million
Pretax Margin
23.76%

Debt

Sales & Book Value

Annual Sales
$759.12 million
Cash Flow
$2.84 per share
Book Value
$18.43 per share

Miscellaneous

Free Float
75,818,000
Market Cap
$5.33 billion
Optionable
Optionable
Beta
1.05

Key Executives

  • Daniel T. ScavillaDaniel T. Scavilla
    President, Chief Executive Officer & Director
  • Keith W. PfeilKeith W. Pfeil
    CFO, Chief Accounting Officer & Senior VP
  • Kelly G. HullerKelly G. Huller
    Secretary, Senior VP & General Counsel
  • Brian Kearns
    Senior Vice President-Business Development













GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2023?

11 Wall Street analysts have issued 12-month target prices for Globus Medical's stock. Their GMED share price forecasts range from $61.00 to $78.00. On average, they predict the company's share price to reach $70.91 in the next year. This suggests a possible upside of 33.4% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2023?

Globus Medical's stock was trading at $74.27 at the beginning of the year. Since then, GMED shares have decreased by 28.5% and is now trading at $53.14.
View the best growth stocks for 2023 here
.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,870,000 shares, an increase of 50.0% from the February 13th total of 2,580,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is currently 3.4 days. Currently, 5.0% of the shares of the stock are sold short.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Tuesday, February, 21st. The medical device company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. The medical device company had revenue of $274.50 million for the quarter, compared to analyst estimates of $276.40 million. Globus Medical had a net margin of 18.59% and a trailing twelve-month return on equity of 11.93%. The business's revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share guidance of $2.30-$2.30 for the period, compared to the consensus estimate of $2.34. The company issued revenue guidance of $1.10 billion-$1.10 billion, compared to the consensus revenue estimate of $1.12 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (2.32%), GW&K Investment Management LLC (1.71%), Geneva Capital Management LLC (1.43%), JPMorgan Chase & Co. (1.34%), Geode Capital Management LLC (1.20%) and Wells Fargo & Company MN (1.19%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $53.14.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $5.33 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does Globus Medical have?

The company employs 2,600 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 3/25/2023 by MarketBeat.com Staff